PROTAC-based MDM2 degrader (Ascentage Pharma)

N/A

Report date: 2025/03/20 09:24:35
NME

Base Information

Drug NamePROTAC-based MDM2 degrader (Ascentage Pharma)
Drug Alias NamePROTAC-based MDM2 degrader (University of Michigan)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp53-binding protein Mdm-2 inhibitors
Targetsp53-binding protein Mdm-2
Therapy Area/IndicationsLeukemiaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesUniversity Of Michigan
China Registration ClassN/A

Develop Information

Active CompaniesAscentage Pharma Group International
Inactive CompaniesN/A
Active IndicationsLeukemia
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A